Surrogate End Points and Patient-Reported Outcomes for Novel Oncology Drugs Approved Between 2011 and 2017

被引：16
作者：
Zettler, Marjorie [1 ]
Basch, Ethan [2 ]
Nabhan, Chadi [3 ]
机构：
[1] Cardinal Hlth, Cardinal Hlth Specialty Solut, Dublin, OH USA
[2] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA
[3] Aptitude Hlth, 5901-C Peachtree Dunwoody Rd NE,Ste 200, Atlanta, GA 30328 USA
来源：
JAMA ONCOLOGY | 2019年 / 5卷 / 09期
关键词：
D O I：
10.1001/jamaoncol.2019.1760
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1358 / 1359
页数：2
相关论文
共 5 条
[1]   Beyond the FDA PRO Guidance: Steps toward Integrating Meaningful Patient-Reported Outcomes into Regulatory Trials and US Drug Labels [J].
Basch, Ethan .
VALUE IN HEALTH, 2012, 15 (03) :401-403
[2]   Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13 [J].
Davis, Courtney ;
Naci, Huseyin ;
Gurpinar, Evrim ;
Poplavska, Elita ;
Pinto, Ashlyn ;
Aggarwal, Ajay .
BMJ-BRITISH MEDICAL JOURNAL, 2017, 359
[3]   Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals [J].
Kim, Chul ;
Prasad, Vinay .
JAMA INTERNAL MEDICINE, 2015, 175 (12) :1992-1994
[4]   Quality of Life, Overall Survival, and Costs of Cancer Drugs Approved Based on Surrogate Endpoints [J].
Rupp, Tracy ;
Zuckerman, Diana .
JAMA INTERNAL MEDICINE, 2017, 177 (02) :276-277
[5]  
U.S.FDA, TABL SURR ENDP WERE
1